A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

Jiaying Chen,Qinghai Ji,Junning Cao,Dongmei Ji,Chunmei Bai,Yansong Lin,Bin Pan,Guofang Sun,Jing Li,Chuan Qi,Ye Hua

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

2017

Jiaying Chen
Qinghai Ji
Junning Cao
Dongmei Ji
Chunmei Bai
Yansong Lin
Bin Pan
Guofang Sun
Jing Li
Chuan Qi
Ye Hua

6037Background: Sulfatinib is an oral tyrosine kinase inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor 1 (FGFR 1), and Colony Stimulating F...

Keywords:

Refractory
Oncology
Thyroid cancer
Multicenter trial
Pathology
Medullary thyroid cancer
Sulfatinib
Medicine
Internal medicine
Kinase
Cancer research
Tyrosine-kinase inhibitor
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations